Trials / Unknown
UnknownNCT01181388
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Beijing Anzhen Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | administration of tirofiban by thrombus aspiration catheter in infarct-related artery | a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI |
| PROCEDURE | administration of tirofiban by guide catheter | a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-04-01
- Completion
- 2012-10-01
- First posted
- 2010-08-13
- Last updated
- 2010-08-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01181388. Inclusion in this directory is not an endorsement.